RxDoctor Payments Data

Jana McKenzie, MD

Internal Medicine · West Palm Beach, FLNPI 1831147578

Payments from drug & device makers

$1,424in general payments, 2019–2025

Across 32 payments — averaging $44.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$203
  • Enterra Medical, Inc.$179
  • Amgen$168
  • Johnson & Johnson$159
  • Intuitive Surgical$155
  • GSK$122
  • plus $437 from 14 others

What the payments were for

  • Food & beverage$1,424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,424 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$120,730
Medicare patients
44
Services billed
6,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan32$29,223
OzempicSemaglutide30$27,812
MounjaroTirzepatide17$15,530
Tadalafil12$1,418
Methenamine Hippurate20$1,282
Quetiapine Fumarate42$1,127
Bupropion XlBupropion Hcl31$1,021
Valsartan34$888
Spironolactone40$750
Escitalopram Oxalate61$583
Ezetimibe27$575
Ipratropium Bromide23$503
Atorvastatin Calcium37$488
Rosuvastatin Calcium66$485
Montelukast Sodium30$445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$67$29,22332 claims
Lilly USA, LLCMounjaro$43$15,53017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →